Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced.
Thrombotic microangiopathy (TMA) is one of the most severe complications of stem cell transplantation (SCT). Endothelial cell injury caused by the toxic effects of high-dose chemoradiotherapy is likely the primary event in pathogenesis. The incidence, clinical settings, and risk factors for TMA in the era of nonmyeloablative conditioning have not been well defined. The data on 147 consecutive SCTs in a single center were collected, and patients with TMA were identified. Patient characteristics, response to therapy, and outcome were recorded, and risk factors were determined. TMA occurred in 22 of 147 transplantations, with a projected incidence of 20% +/- 4%. TMA occurred in 3 clinical settings: classic multifactorial TMA, TMA associated with severe hepatic graft-versus-host disease (GVHD), and TMA associated with second SCT, with a projected incidence of 8% +/- 3%, 73% +/- 14%, and 70% +/- 16% of patients at risk, respectively. TMA occurred after 23% +/- 6% of nonmyeloablative and 16% +/- 5% of myeloablative conditioning regimens (not significant). Univariate analysis determined SCT from unrelated donors, SCT during advanced or active disease, second SCT within 6 months of a prior SCT, and acute GVHD as risk factors for TMA. The last 2 factors remained significant in a multivariate model. Thirty-two percent of patients responded to therapy. The peri-TMA mortality rate was 68% +/- 10%. Six patients had diffuse alveolar hemorrhage complicating TMA. SCT-associated TMA is a relatively common complication with unsatisfactory therapy and grim prognosis. Fludarabine-based nonmyeloablative conditioning does not confer a lesser risk for TMA. This observation may relate to the selective use of these regimens in elderly and heavily pretreated patients or to the lack of reduction of GVHD with these regimens, and fludarabine itself may be involved in causing endothelial damage. Further exploration of novel preventive and therapeutic measurements is required in high-risk settings.
Shimoni
Avichai
A
The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.il
Yeshurun
Moshe
M
Hardan
Izhar
I
Avigdor
Abraham
A
Ben-Bassat
Isaac
I
Nagler
Arnon
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D064420:Drug-Related Side Effects and Adverse Reactions; D042783:Endothelial Cells / Q000473:pathology; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D016491:Peripheral Vascular Diseases / Q000150:complications / Q000209:etiology* / Q000401:mortality / Q000473:pathology; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D033581:Stem Cell Transplantation; D013927:Thrombosis / Q000150:complications / Q000209:etiology* / Q000401:mortality / Q000473:pathology; D019172:Transplantation Conditioning / Q000009:adverse effects*; D016896:Treatment Outcome